Ceterix Orthopaedics announced it has entered into a term loan agreement with CRG and certain of its affiliate funds, providing Ceterix with up to $35 million of available borrowing capacity.

We are excited to have further support to continue our mission to save the meniscus and improve the lives of patients suffering from knee injuries, said John McCutcheon, president and CEO of Ceterix Orthopaedics. This flexible financing will allow us to continue expanding the possibilities of meniscus repair through additional investment in innovation and clinical research.

CRG is dedicated to providing growth capital to innovative commercial-stage healthcare companies, said Charles Tate, Chairman of CRG. We are excited to partner with Ceterix as the company continues to advance its new technologies and improve patient outcomes in the meniscal surgery space.

Menlo Park, CA-based Ceterix Orthopaedics develops surgical tools that expand and improve what is possible for physicians who treat soft tissue injuries such as meniscus tears, hip and shoulder labrum tears, and rotator cuff tears.

Founded in 2003, CRG (f/n/a Capital Royalty) is a healthcare-focused investment firm with over $2 billion of assets under management that provides capital to healthcare companies primarily through structured debt and senior secured loans.